These 3 stocks are ready to rise at least 50%

The fear that the corona virus will continue to spread has not dampened investor appetite. Key indices continue to trade at all-time highs, with both the S&P 500 and Nasdaq Composite reaching new milestones earlier this week.

According to Tony Dwyer, chief market strategist at Canaccord, there are several reasons why the outlook for the markets remains optimistic. “They have full employment with simple money and high availability of money, high trust and a thousand year population that goes into the years of household formation,” he said.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "With this in mind, we called three of Canaccord's most recent stock selections, which the reputable investment firm believes will grow in the coming months – over 50% each – to make sure we do it through TipRanks Stock Screener Tool to make sure other analysts agree with Canaccord. Let’s take a closer look at that. “Data-reactid =” 13 “> Against this backdrop, we have released three of Canaccord’s most recent stock selections, which the reputable investment firm believes will rise in the coming months – each by over 50%. To be sure, we run using the TipRanks Stock Screener tool to make sure other analysts agree with Canaccord, so let’s take a closer look.

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "SeaSpine Holdings (shavings)“data-reactid =” 14 “>SeaSpine Holdings (shavings)

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "SeaSpines 2020 got off to a good start; according to Cannacord's, it is Medical device companies up 36% since the beginning of the year Kyle RoseMore will come. “data-reactid =” 15 “> SeaSpines 2020 got off to a good start. The medical device company has grown 36% since the beginning of the year. According to Kyle Rose of Cannacord, there is one more to come.

SeaSpine designs, develops and sells surgical devices for the treatment of spinal disorders. The company’s growing product portfolio has grown impressively. 22 launches between 2016 and 2018, 7 more last year and another 12 are expected this year.

<p class = "Canvas Atom Canvas Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The global market for spinal implants is the largest business area within The Space is worth over $ 10 billion for the musculoskeletal system and is ideal for smaller, pure gaming companies like SeaSpine. The focus of the spine market on education and doctor relationships rewards innovations. The company has invested strategically in its sales branch and also has a strong sales channel. “Data-reactid =” 17 “> The global market for spinal implants is the largest department in the musculoskeletal system and is worth over $ 10 billion. Ideal for smaller, pure gaming companies such as SeaSpine. The focus of the spine market on education and doctor relationships rewards innovations. The company has invested strategically in its sales branch and also has a strong sales channel.

Rose sees “smooth sailing and takeover for SPNE in 2020”. The 5-star analyst names new products, improved distribution and a clean balance sheet as reasons to be optimistic.

He said: “SeaSpine management has clearly focused on developing new products to stand out from an older, older portfolio. New, innovative products are not only the key to combating competitive pressures, but are also critical to maintaining distributor mindshare as the company works to retain key existing distributors and transition to exclusive relationships that provide incentives for short and long term relationships offer long-term growth. “

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "So it is no surprise to experience this rose initiated reporting via SPNE with a buy rating. The price target of $ 25 conveys the analyst's belief that SeaSpine can increase its stock price by another 55% over the next 12 months. (To monitor Rose's track record, Click here) “data-reactid =” 20 “> It is therefore no surprise to learn that Rose initiated reporting on SPNE with a buy rating. The price target of USD 25 conveys the analyst’s conviction that SeaSpine will increase its share price by a further 55% may be the next 12 months. (To see Rose’s track record, Click here)

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The street adapts and aligns itself; SeaSpine's Moderate The buy-consensus rating is broken down into 5 purchases and 1 sale. At $ 20.50, the average target price indicates a further possible upward trend of 27%. (See SeaSpine stock analysis on TipRanks) “data-reactid =” 21 “> The street adjusts and agrees; SeaSpine’s consensus rating for moderate buying is divided into 5 purchases and 1 sale. At $ 20.50, the average price target points to another possible uptrend of 27 % hin (see SeaSpine) stock analysis on TipRanks)

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "American superconductor (AMSC)“data-reactid =” 30 “>American superconductor (AMSC)

From spine solutions to solving energy problems where we come across American Superconductor. The company for energy technology develops and manufactures power supply systems and superconducting wires and offers solutions on a megawatt scale worldwide. The company takes a two-pronged approach that focuses on both wind and grid.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "According to Canaccord Chip MooreThe management of electricity flows through AMSC is tied to several attractive long-term worldly drivers. The 5-star analyst notes that, given the increasing spread of distributed generation plants and the accelerated introduction of electric vehicles, the need for increased grid reliability is critical. AMSC’s REG (Resilient Electric Grid) connects critical substations through its Amperium HTS cable (which allows systems to flexibly redirect power), which in turn helps address this issue in urban environments. The first key project (ComEd) is making progress in Chicago, and more will follow if it turns out to be a success. “Data-reactid =” 32 “> According to Canaccord’s Chip Moore, AMSC’s power flow management is tied to several attractive long-term projects AMSC’s REG (Resilient Electric Grid) connects critical substations through its Amperium HTS cable (which allows systems to flexibly redirect power), which in turn helps to address this problem in urban environments The first key project (ComEd) is making progress in Chicago, and more will follow if it turns out to be a success.

Moore commented, “We find management is making good progress in commercializing multiple attractive markets (beyond the wind) and supporting lower future volatility and a way to generate sustainable cash. With cash and investments of $ 68 million on the balance sheet, a more reasonable valuation after last year’s retreat and a rapidly approaching breakeven point (~ $ 25 million in sales per quarter), we see good future potential for aggressive growth-oriented investors , “

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "What does it mean then? It means the 5-star -Analyst initiates AMSC reporting with a buy rating. Moore sets a price target of $ 13, indicating a possible upward trend of 65%. (To track Moore's track record, Click here) “data-reactid =” 38 “> What does it mean? This means that the 5-star analyst initiates reporting on AMSC with a buy rating. Moore sets a target price of $ 13, which is a potential plus of 65%. (To Look at Moore’s track record. Click here)

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The grid is currently working quietly on the street. With only one additional analysts interfering with AMSC's outlook, but the additional purchase means that the energy solutions provider is classified as a moderate buy, with an average price target of $ 13.5, investors could make a profit of 72 over the coming years % achieve months. (See American Superconductor stock analysis on TipRanks) “data-reactid =” 39 “> The network is currently quietly operating on the street and only one other analyst is interfering to assess AMSC’s prospects. However, the additional purchase means that the provider of energy solutions is a moderate purchase With an average target price of $ 13.5, investors could make a 72% profit in the coming months (see American Superconductor stock analysis on TipRanks).

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "Akero Therapeutics (AKRO)“data-reactid =” 48 “>Akero Therapeutics (AKRO)

This clinical stage biotechnology was only founded in 2017 and went public in June last year. Akero Therapeutics is a young company, but has already caused a sensation on the street. The stock price has risen 54% since the first day on the market.

The company’s focus is on developing medicines to reverse the course of serious metabolic diseases, especially those with high medical needs (orphan diseases).

Akero’s main candidate is AKR-001, a treatment for NASH (Non-Alcoholic SteatoHepatitis), a fatty liver disease for which no specific drugs are currently available. The NASH drug market is expected to grow significantly over the next few years, and whoever comes up with a viable solution can make good money. The drug is currently in a phase 2 trial. The key dates are expected for this quarter.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "According to promising data from a phase 1 study by Cannacord Edward Nash believes Akeros AKR-01 “has shown superior advantages in molecular design”. In addition, the 4-star analyst believes that Akero has an impressive management team with “significant experience in biotech and pharmaceutical finance, drug development, regulation and market launch”. “Data-reactid =” 52 “> According to promising data from a phase 1 trial, Cannacord’s Edward Nash believes Akeros AKR-01” has shown superior advantages in molecular design. “The 4-star analyst also believes that Akero has an impressive management team with “significant experience in biotech and pharmaceutical finance, drug development, regulation and market launch”.

Nash said, “Our model assumes a stage 1-3 NASH population with stage 1-3 fibrosis, a 35% diagnosis rate, and an 80% treatment rate, leading to a 2.1 million target market for AKR 001 treatment comes into question. Assuming a modest 5% penetration rate in 2029, the year of our model, and pricing consistent with branded type 2 diabetes medicines, we are conservatively assuming Akero has global sales of ~ $ 1.1 billion will achieve. With approximately $ 148 million in cash and equivalents reported at the end of the third quarter 19, we believe the company is well capitalized to reach significant clinical milestones before funding is required. “

<p class = "Canvas Atom Canvas Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Accordingly, Nash initiated the reporting of the NASH fighter with a Buy recommendation and a price target of USD 36. The potential upward trend should the target be reached is 52%. (To see Nash's track record, Click here) “data-reactid =” 54 “> Accordingly, Nash initiated reporting on the NASH fighter with a buy recommendation and a target price of USD 36. The potential upward trend if the target is reached is 52% record to watch, Click here)

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "What keeps the street from Akeros prospects? Recommended retail – 5 in Indeed – give promising biotechnology a strong buying consensus rating. With an average price target of $ 32.8, analysts see the potential for a 31% increase in the share price in the coming year.See Akero stock analysis on TipRanks) “data-reactid =” 55 “> What does the road hold about Akeros prospects? The only buy ratings – 5 – give promising biotechnology a strong buy consensus rating. With an average price target of $ 32.8, analysts see the potential for a 31% Share price increase in the coming year (see Akero stock analysis on TipRanks)

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.